Myeloma Paper of the Day, October 19th, suggested by Robert Orlowski

Robert Orlowski shared a post on X:

“Myeloma Paper of the Day: Case series of patients with immune effector cell-associated enterocolitis after CAR T-cell for myeloma, with median onset 92.5 days and treatment first with steroids, though early infliximab or vedolizumab use may hasten resolution:”

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

Authors: Gliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, Jinming Song, Carlos M. Morán-Segura, Jonathan V. Nguyen, Lazaros Lekakis, Sebastian Fernandez-Pol, Annie N. Samraj, Kikkeri N. Naresh, Mariola Vazquez-Martinez, Rachid C. Baz, Jay Y. Spiegel, Lekha Mikkilineni, John M. Gubatan, Surbhi Sidana, Andre de Menezes Silva Corraes, Nilesh M. Kalariya, Krina K. Patel, Kevin G. Shim, Rafael Fonseca, Christopher Ferreri, Peter M. Voorhees, Shambavi Richard, Cesar Rodriguez Valdes, Sireesha Asoori, Jeffrey L. Wolf, Andrew J. Cowan, Douglas W. Sborov, Frederick L. Locke, Yi Lin, Yinghong Wang and Doris K. Hansen.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response.Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.